Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Mar 17;231(3):e470-e477.
doi: 10.1093/infdis/jiae469.

Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection

Sunwen Chou  1   2 , Drew J Winston  3 , Robin K Avery  4 , Catherine Cordonnier  5 , Rafael F Duarte  6 , Shariq Haider  7 , Johan Maertens  8 , Karl S Peggs  9 , Carlos Solano  10 , Jo-Anne H Young  11 , Joan Gu  12 , Ginger Pocock  12 , Genovefa A Papanicolaou  13
Affiliations
Clinical Trial

Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection

Sunwen Chou et al. J Infect Dis. .

Abstract

Background: Among 547 patients receiving maribavir or valganciclovir for first-episode cytomegalovirus infection after hematopoietic cell transplant, the treatment response rate was 69.6% and 77.4% respectively. Development of maribavir and ganciclovir resistance was compared after receiving either drug.

Methods: Viral mutations conferring drug resistance were analyzed in plasma DNA extracts at baseline and posttreatment.

Results: Prior antiviral drug exposure was limited, with only 2 instances of baseline drug resistance detected. An equal number (n = 241) received valganciclovir or maribavir for at least 21 days (median, 55-56 days). Among them, drug resistance mutations were detected in 24 (10%) maribavir recipients at 35-125 days (median, 56 days) after starting therapy, including in 12 of 14 who experienced a viral load rebound while on therapy. Ganciclovir resistance mutations developed in 6 (2.5%) valganciclovir recipients at 66-110 days (median, 90 days). One maribavir recipient developed a novel UL97 gene mutation (P-loop substitution G343A) that conferred strong maribavir and ganciclovir resistance in vitro. Viral clearance was confirmed in 17 (74%) of 23 patients with emergent maribavir resistance after retreatment with an alternative CMV antiviral drug.

Conclusions: After 3-8 weeks of therapy, maribavir resistance emerged earlier and more frequently than ganciclovir resistance but was usually treatable using alternative therapy. Clinical Trials Registration. NCT02927067 (AURORA).

Keywords: antiviral drug resistance; antiviral therapy; cytomegalovirus; maribavir; valganciclovir.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Baseline viral loads and interval to emergence of maribavir resistance. Each point represents the baseline CMV load and days to emergence of maribavir resistance for an individual patient. There is no correlation of the parameters (Pearson correlation coefficient −0.04). Abbreviations: CMV, cytomegalovirus; DRM, drug resistance mutation.
See this image and copyright information in PMC

References

    1. Ljungman P, de la Camara R, Robin C, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European conference on infections in leukaemia (ECIL 7). Lancet Infect Dis 2019; 19:e260–72. - PubMed
    1. Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med 2017; 377:2433–44. - PubMed
    1. Avery RK, Alain S, Alexander BD, et al. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial. Clin Infect Dis 2022; 75:690–701. - PMC - PubMed
    1. Papanicolaou G, Avery RK, Cordonnier C, et al. Treatment for first cytomegalovirus infection post-hematopoietic cell transplant in the AURORA trial: a multicenter, double-blind, randomized, phase 3 trial comparing maribavir with valganciclovir. Clin Infect Dis 2024; 78:562–72. - PMC - PubMed
    1. Chou S. Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance. Antimicrob Agents Chemother 2015; 59:6588–93. - PMC - PubMed

Publication types

MeSH terms

Associated data